FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207319020> ?p ?o ?g. }

• W3207319020 endingPage "S1005" @default.
• W3207319020 startingPage "S1004" @default.
• W3207319020 abstract "Immunotherapy (IO) provides improved treatment efficacy and survival in NSCLC patients. However, data on this treatment are released from clinical trials. There is a need for a real world data experience in IO in Lebanon. The type of metastasis in for telling of response results still well unknown currently. In this retrospective study, 124 patients were enrolled, all were stage IIIB/IV NSCLC who received IO with nivolumab, pembrolizumab or atezolizumab at any line of treatment, and were recruited between February 2012 and august 2020. Patients with no follow up or available data, or those who received less than 6 cycles of IO were excluded. IO was continued until progression, death or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression free survival (PFS) from start of IO. PFS1 or PFS2 are defined as duration from starting 1st or 2nd lines of treatment respectively to progression. for Secondary endpoints include immune related toxicity. Multivariable analysis was made on correlation of metastasis type and survival. Across two Lebanese medical institutions (Mount Lebanon Hospital and Hotel Dieu de France Hospital-Saint Joseph university), we screened 140 patients, and included 124 patients who met the inclusion criteria. Median age at diagnosis was 69 years old, 28.5% were female, and 68.6% were at stage IV, 67.6% had adenocarcinoma and 32.4% had squamous cell carcinoma. Site of metastasis found were bone (22.8%), adrenal (20.3%), pleural (17.1%), brain (11.4%), liver (5.9%), and other (12.2%). Most patients (58.1%) had received chemotherapy alone and 41 % received immunotherapy at first line. At second line, majority of patients (77.1%) received immunotherapy. Median PFS1 was 7.55 months. Median PFS2 was 8.8 months. But no significant difference association was found between those who received chemotherapy and those who received immunotherapy as a first line (HR=1.63; p=0.542; 95% CI 0.34-7.79) or as a second line (HR=0.53; p=0.189; 95% CI 0.21-1.36). Rash was the most frequent immune related adverse events observed (16.13%) followed by pneumonitis (10.48%). No grade 3 or 4 immune related adverse events were seen during follow-up. Median OS was 14 months. A shorter overall survival was seen in patients who had bone metastasis (HR=3.23; p=0.002; 95% CI 1.53-6.82), but not those who had adrenal, brain or liver metastasis In real world, IO was well tolerated and our Lebanese data is comparable to international data. Concerning sites of metastasis and association with clinical outcome, we hypothesize that bone metastasis may influence efficacy to immunotherapy" @default.
• W3207319020 created "2021-10-25" @default.
• W3207319020 creator A5014053790 @default.
• W3207319020 creator A5020046919 @default.
• W3207319020 creator A5036749656 @default.
• W3207319020 creator A5067379651 @default.
• W3207319020 creator A5068500022 @default.
• W3207319020 date "2021-10-01" @default.
• W3207319020 modified "2023-09-26" @default.
• W3207319020 title "P10.13 Real World Outcomes for Non Small Cell Lung Cancer Treated With Checkpoint Inhibitors in Lebanon, A Multicenter Observational Study" @default.
• W3207319020 doi "https://doi.org/10.1016/j.jtho.2021.08.318" @default.
• W3207319020 hasPublicationYear "2021" @default.
• W3207319020 type Work @default.
• W3207319020 sameAs 3207319020 @default.
• W3207319020 citedByCount "0" @default.
• W3207319020 crossrefType "journal-article" @default.
• W3207319020 hasAuthorship W3207319020A5014053790 @default.
• W3207319020 hasAuthorship W3207319020A5020046919 @default.
• W3207319020 hasAuthorship W3207319020A5036749656 @default.
• W3207319020 hasAuthorship W3207319020A5067379651 @default.
• W3207319020 hasAuthorship W3207319020A5068500022 @default.
• W3207319020 hasBestOaLocation W32073190201 @default.
• W3207319020 hasConcept C121608353 @default.
• W3207319020 hasConcept C126322002 @default.
• W3207319020 hasConcept C143998085 @default.
• W3207319020 hasConcept C203092338 @default.
• W3207319020 hasConcept C2775949291 @default.
• W3207319020 hasConcept C2776232967 @default.
• W3207319020 hasConcept C2776256026 @default.
• W3207319020 hasConcept C2776694085 @default.
• W3207319020 hasConcept C2777701055 @default.
• W3207319020 hasConcept C2779013556 @default.
• W3207319020 hasConcept C2779422266 @default.
• W3207319020 hasConcept C2780030458 @default.
• W3207319020 hasConcept C2780057760 @default.
• W3207319020 hasConcept C2780739268 @default.
• W3207319020 hasConcept C2781182431 @default.
• W3207319020 hasConcept C535046627 @default.
• W3207319020 hasConcept C71924100 @default.
• W3207319020 hasConceptScore W3207319020C121608353 @default.
• W3207319020 hasConceptScore W3207319020C126322002 @default.
• W3207319020 hasConceptScore W3207319020C143998085 @default.
• W3207319020 hasConceptScore W3207319020C203092338 @default.
• W3207319020 hasConceptScore W3207319020C2775949291 @default.
• W3207319020 hasConceptScore W3207319020C2776232967 @default.
• W3207319020 hasConceptScore W3207319020C2776256026 @default.
• W3207319020 hasConceptScore W3207319020C2776694085 @default.
• W3207319020 hasConceptScore W3207319020C2777701055 @default.
• W3207319020 hasConceptScore W3207319020C2779013556 @default.
• W3207319020 hasConceptScore W3207319020C2779422266 @default.
• W3207319020 hasConceptScore W3207319020C2780030458 @default.
• W3207319020 hasConceptScore W3207319020C2780057760 @default.
• W3207319020 hasConceptScore W3207319020C2780739268 @default.
• W3207319020 hasConceptScore W3207319020C2781182431 @default.
• W3207319020 hasConceptScore W3207319020C535046627 @default.
• W3207319020 hasConceptScore W3207319020C71924100 @default.
• W3207319020 hasIssue "10" @default.
• W3207319020 hasLocation W32073190201 @default.
• W3207319020 hasOpenAccess W3207319020 @default.
• W3207319020 hasPrimaryLocation W32073190201 @default.
• W3207319020 hasRelatedWork W2606203880 @default.
• W3207319020 hasRelatedWork W2622595542 @default.
• W3207319020 hasRelatedWork W2948845624 @default.
• W3207319020 hasRelatedWork W3004989554 @default.
• W3207319020 hasRelatedWork W3177447256 @default.
• W3207319020 hasRelatedWork W3215044659 @default.
• W3207319020 hasRelatedWork W3216520672 @default.
• W3207319020 hasRelatedWork W4221037704 @default.
• W3207319020 hasRelatedWork W4313857758 @default.
• W3207319020 hasRelatedWork W4317566941 @default.
• W3207319020 hasVolume "16" @default.
• W3207319020 isParatext "false" @default.
• W3207319020 isRetracted "false" @default.
• W3207319020 magId "3207319020" @default.
• W3207319020 workType "article" @default.